[Efficacy of the chemosensitivity test using collagen gel matrix-supported culture system for urogenital tumors].
BACKGROUND
We evaluated the usefulness of in vitro tumor culture system using a specialized collagen gel matrix (CGM assay) as a chemosensitivity test.


METHODS
Chemosensitivity results of CGM assay were compared with other in vivo and in vitro assays on an implantable murine bladder tumor cell line (MBT-2). In addition we investigated the possibility of the clinical use of CGM assay using clinical specimens obtained from urogenital malignant tumor patients by comparing the result with that of the other chemosensitivity test, SDI testing using single cells (conventional SDI test). Methods of CGM assay were as follows. Tumor tissues on the collagen gel matrices were incubated under the existence of anticancer drugs following 4 days preculture. Drug sensitivities were evaluated by counting the number of viable cells adjusted to the tumor weight.


RESULTS
Inhibition rates in MBT-2 were high in the order of mitomycin C, cisdiamminedichloroplatinum (II), (2"R)-4'-0-tetrahydropyranyl adriamycin. Four of 6 anticancer drugs were decided as chemosensitive drugs. These results corresponded to the results of the antitumor effects on subcutaneously transplanted MBT-2 in vivo, moreover was correlated well with those of the conventional SDI test. Twenty of 22 cases, including 11 of 13 bladder cancer cases, 1 of 3 renal cancer cases, 2 of 3 testicular cancer cases and 1 of 1 adrenal cortical cancer cases, were evaluable in the clinical study of the CGM assay. Corresponding rates between the results of the CGM assay and those of the conventional SDI test performed simultaneously in 12 cases were excellent for each anticancer drug.


CONCLUSIONS
This CGM assay can serve as an effective tool for chemosensitivity testing because of its convenience and high evaluable rate.
Ogihara
M
M
Department of Urology, Fukuishima Medical College, Japan.
Aikawa
K
K
Ishibashi
K
K
Irisawa
C
C
Shiraiwa
Y
Y
Koseki
K
K
Ishiwata
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology; D002292:Carcinoma, Renal Cell / Q000473:pathology*; D002945:Cisplatin / Q000494:pharmacology; D003094:Collagen; D003470:Culture Media; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D005047:Etoposide / Q000494:pharmacology; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology*; D051379:Mice; D008809:Mice, Inbred C3H; D016685:Mitomycin / Q000494:pharmacology; D001749:Urinary Bladder Neoplasms / Q000473:pathology*; D014747:Vinblastine / Q000494:pharmacology
D000970:Antineoplastic Agents; D003470:Culture Media; D001761:Bleomycin; D016685:Mitomycin; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D003094:Collagen; C027260:pirarubicin; D002945:Cisplatin